Amgen partners with Immatics Biotechnologies to develop cancer drugs

By Staff Report  /  Monday, January 9th, 2017  /  Central Coast Health Watch, Latest news, Tri-County Public Companies  /  Comments Off on Amgen partners with Immatics Biotechnologies to develop cancer drugs

Thousand Oaks biotech company Amgen formed a potential $500 million partnership with Immatics Biotechnologies GmbH to research and develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers, the company announced on Jan. 9. Under the terms of the agreement, Immatics will receive $30 million upfront and can receive more than $500 million in development, regulatory Read More →